匹多莫德联合阿维A胶囊对复发性尖锐湿疣HPV亚型T淋巴细胞亚群的影响

发布时间：2018-06-28 01:30

  本文选题：匹多莫德 + 阿维A胶囊　； 参考：《临床医学》2016年11期

【摘要】：目的探讨匹多莫德联合阿维A胶囊治疗复发性尖锐湿疣(CA)人乳头瘤病毒(HPV)亚型的应用价值。方法以随机数字表法将66例复发性CA HPV亚型患者分为两组,每组33例。以接受二氧化碳激光治疗者为对照组,以在接受二氧化碳激光治疗同时联合应用匹多莫德及阿维A胶囊治疗者为观察组。对比两组治疗前后T淋巴细胞亚群变化情况及临床治疗效果。结果两组间入组时DLQI评分、SCL-90评分、CD_3~+、CD_4~+、CD8+百分比及CD_4~+/CD8+比较差异未见统计学意义(P0.05);而在接受治疗3个月后,观察组DLQI评分及CD8+百分比低于对照组,SCL-90评分、CD_3~+、CD_4~+百分比及CD_4~+/CD8+高于对照组(P0.05)。观察组治疗总有效率明显高于对照组(P0.05)。观察组治疗不良反应发生率明显低于对照组(P0.05)。结论匹多莫德联合阿维A胶囊治疗可有效改善复发性CA HPV亚型免疫指标,并可在有效的提高治疗效果的同时,显著的降低不良反应发生率。
[Abstract]:Objective to evaluate the clinical value of pidomod combined with avea capsule in the treatment of recurrent condyloma acuminatum (CA) human papillomavirus (HPV) subtype. Methods 66 patients with recurrent CA HPV subtype were randomly divided into two groups, 33 cases in each group. The control group was treated with carbon dioxide laser and those who were treated by carbon dioxide laser combined with pidomod and avea capsule as the observation group. The changes of T lymphocyte subsets before and after treatment were compared between the two groups. Results there was no significant difference in DLQI score, SCL-90 score, CD3 ~ + CD4 ~ / CD8% and CD4 ~ / CD8 between the two groups (P0.05), but after 3 months of treatment, there was no significant difference in the percentage of CD3 / CD8 and CD4 / CD8 between the two groups (P0.05), but after 3 months of treatment, there was no significant difference between the two groups. The DLQI score and CD8 percentage in the observation group were lower than those in the control group. The percentage of CD3 / CD8 and CD4 / CD8 were significantly higher in the observation group than in the control group (P0.05). The total effective rate in the observation group was significantly higher than that in the control group (P0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group (P0.05). Conclusion Pidomod combined with avea capsule can effectively improve the immune index of recurrent CA HPV subtype and decrease the incidence of adverse reactions.
【作者单位】： 广东省鹤山市人民医院;广州市第一人民医院;
【分类号】：R752.53
，

本文编号：2076114